OncoMatch/Clinical Trials/NCT06483100
Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Is NCT06483100 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Elrantamab and clonoSEQ for multiple myeloma.
Treatment: Elrantamab · clonoSEQ — This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy data for a personalized maintenance approach using bone marrow-based MRD testing (clonoSEQ) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: autologous hematopoietic cell transplant — frontline
Received autologous hematopoietic cell transplantation (with or without tandem transplant) as part of frontline therapy for newly diagnosed IgG or IgA multiple myeloma
Must have received: proteasome inhibitor — frontline
Received frontline treatment with at least a triplet regimen including a PI and an IMID (+/- an anti-CD38 antibody)
Must have received: IMID — frontline
Received frontline treatment with at least a triplet regimen including a PI and an IMID (+/- an anti-CD38 antibody)
Cannot have received: BCMA-based treatment
Prior BCMA-based treatment
Lab requirements
Blood counts
Platelets ≥ 75 k/cumm; ANC ≥ 1.0 k/cumm; Hemoglobin ≥ 8 g/dL without the use of growth factors or transfusion for at least 2 weeks
Kidney function
Creatinine clearance ≥ 30 ml/min
Liver function
Total bilirubin ≤ 2 × ULN (≤ 3 x ULN if documented Gilbert's syndrome); AST and ALT ≤ 2.5 × ULN
Adequate bone marrow and organ function within 28 days prior to start of treatment as defined below: * Platelets ≥ 75 k/cumm * Absolute neutrophil count ≥ 1.0 k/cumm * Hemoglobin ≥ 8 g/dL without the use of growth factors or transfusion for at least 2 weeks. * Total bilirubin ≤ 2 × upper limit of normal (ULN; ≤ 3 x ULN if documented Gilbert's syndrome) * Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 × ULN * Creatinine clearance ≥ 30 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify